Quantbot Technologies LP boosted its stake in Cencora, Inc. (NYSE:COR – Free Report) by 39.2% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 81,560 shares of the company’s stock after acquiring an additional 22,987 shares during the quarter. Cencora comprises about 0.9% of Quantbot Technologies LP’s holdings, making the stock its largest holding. Quantbot Technologies LP’s holdings in Cencora were worth $18,375,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of COR. Rise Advisors LLC acquired a new stake in shares of Cencora during the first quarter valued at about $25,000. Legacy Bridge LLC purchased a new position in Cencora in the first quarter valued at about $27,000. New Millennium Group LLC acquired a new stake in Cencora during the 2nd quarter valued at approximately $26,000. TCTC Holdings LLC acquired a new position in shares of Cencora in the 1st quarter valued at approximately $29,000. Finally, TFO Wealth Partners LLC acquired a new position in shares of Cencora in the 1st quarter valued at approximately $30,000. Institutional investors and hedge funds own 97.52% of the company’s stock.
Insider Buying and Selling
In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the transaction, the insider now directly owns 19,980,000 shares of the company’s stock, valued at approximately $4,806,388,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Steven H. Collis sold 10,755 shares of the stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the transaction, the chief executive officer now owns 285,088 shares of the company’s stock, valued at $63,323,746.56. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of Cencora stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the sale, the insider now owns 19,980,000 shares in the company, valued at $4,806,388,800. The disclosure for this sale can be found here. Insiders have sold a total of 4,450,399 shares of company stock valued at $1,070,392,799 in the last quarter. Company insiders own 15.80% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on Cencora
Cencora Stock Performance
Shares of COR stock opened at $239.88 on Monday. The company has a market cap of $47.84 billion, a P/E ratio of 26.25, a PEG ratio of 1.55 and a beta of 0.44. The business has a 50 day moving average of $233.92 and a two-hundred day moving average of $233.24. Cencora, Inc. has a 52 week low of $175.50 and a 52 week high of $247.66. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93.
Cencora (NYSE:COR – Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. The business had revenue of $74.20 billion during the quarter, compared to analyst estimates of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.92 EPS. As a group, analysts anticipate that Cencora, Inc. will post 13.63 EPS for the current year.
Cencora Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were given a dividend of $0.51 per share. The ex-dividend date was Friday, August 9th. This represents a $2.04 annualized dividend and a dividend yield of 0.85%. Cencora’s dividend payout ratio is currently 22.32%.
Cencora Company Profile
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Further Reading
- Five stocks we like better than Cencora
- What Are Growth Stocks and Investing in Them
- 3 Defensive Stock Alternatives to Bonds If Interest Rates Drop
- Pros And Cons Of Monthly Dividend Stocks
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- What is the S&P 500 and How It is Distinct from Other Indexes
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.